Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Cediranib
Cat. No.:
OB0225LY-0446
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Cediranib is an oral small molecule tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptor (VEGFR) and is able to inhibit the angiogenic process in tumors.
Synonym:
AZD2171; NSC-732208; 288383-20-0; Recentin; AZD2171; 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
CAS No.:
288383-20-0
Compound CID:
9933475
Formula:
C25H27FN4O3
Formula Weight:
450.51
Specification
Relative Density:
1.285 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Cediranib can be used in tumor biology research to help explore the relationship between tumor growth and angiogenesis.
Library Information
Targets:
Kinases
Receptors:
c-Kit; Flt1; Flt4; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4
Pathways:
Angiogenesis; Tyrosine kinase/adaptors; Autophagy
Plate Number:
AOCL-6
Plate Location:
g3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
83 mg/mL; 184.2 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
4.761
HBA_Count:
5
HBD_Count:
1
Rotatable Bond:
8
